ESC 365 - Clinical implications for patients at persistent ASCVD risk

ESC Premium Access

Clinical implications for patients at persistent ASCVD risk

Session: Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population

Topic: Lipids

Speaker: Doctor J. Saseen (Aurora, US)

Sponsored by National Lipid Association

Event: ESC Congress 2019

Congress Presentation

About the speaker

Doctor Joseph Saseen

University of Colorado Anschutz Medical Campus, Aurora (United States of America)

1 presentation

0 follower

4 more presentations in this session

Clinical trial updates

Speaker: Doctor C. Ballantyne (Houston, US)

The future of lipid management: new therapies for LDL-C lowering

Speaker: Doctor H. Bays (Louisville, US)

Post-activity quiz and discussion

Speaker: Doctor P. MORRIS (Charleston, US)

Questions and answers / Panel discussion

Access the full session

Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population

Speakers: Doctor J. Saseen, Doctor C. Ballantyne, Doctor H. Bays, Doctor P. MORRIS

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by